Wird geladen...
Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis
Risankizumab-rzaa (Skyrizi(®); AbbVie) is a humanized IgG monoclonal antibody directed against interleukin-23p19 (IL-23p19) indicated for the treatment of moderate-to-severe psoriasis in adults who are candidates for systemic therapy or phototherapy. Four pivotal Phase III trials: UltIMMa-1, UltIMMa...
Gespeichert in:
| Veröffentlicht in: | J Inflamm Res |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Dove
2020
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6985981/ https://ncbi.nlm.nih.gov/pubmed/32158251 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JIR.S215196 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|